HBV plus HCV, HCV plus HIV, HBV plus HIV

Current Gastroenterology Reports

Volumn 8, Issue 1, 2006, Pages 67-74

  Park, James S ^b   Saraf, Neeraj ^b   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMDOXOVIR; CLEVUDINE; DEOXYCYTIDINE; DIDANOSINE; ELVUCITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; ERYTHROPOIETIN; FAMCICLOVIR; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SUBSTITUTION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; NEUTROPENIA; PANCREATITIS; PSYCHOPATHY; REVIEW; THROMBOCYTOPENIA; VIRUS TRANSMISSION;

ALGORITHMS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG INTERACTIONS; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIRAL LOAD;

EID: 33645058677     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0066-9     Document Type: Review

References (68)

1. Detels R, Munoz A, McFarlane G: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998, 280:1497-1503.
2. National Institute of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. Hepatology 2002, 36(5):S3-S20.
3. Sherman KE, Rouster SD, Chung RT, et al.: Hepatitis C Virus prevalence among patients infected with human Immunodeficiency virus: a cross sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831-837.
4. Gerlach JT, Diepolder HM, Jung M-C, et al.: Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C. Gastroenterology 1999, 117:933-941.
5. John M, Flexman J, French MA: Hepatitis C virus associated hepatitis following treatment of HIV infected patients with protease inhibitors: an immune restoration disease? AIDS 1998, 12:2289-2293.
6. Woitas RP, Rockstroh JK, Beier I, et al.: Antigen specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis c virus coinfected patients. AIDS 1999, 13:1313-1322.
7. Cribier B, Rey D, Schmitt C, et al.: High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995, 9:1131-1136.
8. Bonacini M, Govindarajan S, Blatt LM, et al.: Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999, 6:203-208.
9. Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus infection and hepatitis C virus coinfected patients. Hepatology 1999, 30:1054-1058.
10. Macias J, Castellano V, Merchante N, et al.: Effect of antiretroviral drugs on liver fibrosis in HIV infected patients with chronic hepatitis C: harmful effect of nevirapine. AIDS 2004, 18:767-774.
11. Mehta SH, Thomas DL, Torbenson M, et al.: The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005, 41:123-131.
12. Kelleher TB, Mehta SH, Bhaskar R, et al.: Prediction of hepatic fibrosis in HIV/HCV coinfection using serum fibrosis markers: The SHASTA index. J Hepatol 2005, 43:78-84.
13. Sulkowski MS, Mehta HS, Torbenson M, et al.: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005, 19:585-592.
14. Puoti M, Bruno R, Soriano V. et al.: Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004, 18:2285-2293.
15. Bica I, McGovern B, Dhar R, et al.: Increasing mortality in end stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492-497.
16. Monto A, Dove LM, Seal KH, et al.: HIV-HCV Coinfected patients followed prospectively for a mean of 4.2 years, have similar rates of death or cirrhosis compared to HCV mono-infected patients. Hepatology 2004, 40(Suppl 1):1212A.
17. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. N Engl J Med 2004, 351:438-450.
18. Chung RT, Anderson J, Volberding P, et al.: Peginterferon alfa -2a plus ribavirin versus interferon alfa 2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N Engl J Med 2004, 351:451-499.
19. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
20. Laguno M, Murillas J, Blanco JL, et al.: Peginterferon alpha 2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 2004, 18:F27-F36.
21. Dieterich DT, Spivak JL: Hematological disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003, 37:533-541.
22. Dieterich D, Sulkowski M, Bini E, et al.: Epoetin-alfa administered once weekly improves anemia in HIV/HCV coinfected patients treated with interferon/ribavirin therapy: a prospective, randomized study. Presented at the 11th conference on Retroviruses and Opportunistic Infections (A824), San Francisco, CA, February 2004.
23. Brau N, Rodriguez-Torres M, Prokupek D, et al.: Treatment of chronic hepatitis C in HIV/HCV coinfection with interferon alpha 2b full course vs. 16 week delayed ribavirin. Hepatology 2004, 39:989-998.
24. Sulkowski MS, Felizarta F, Smith C, et al.: daily vs. 3 times weekly interferon alfa 2b plus ribavirin for the treatment of hepatitis C infection in HIV infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004, 35:464-472.
25. Kakuda TN, Brinkman K: Mitochondrial toxic effects and ribavirin. Lancet 2001, 357:1802-1803.
26. Taylor LE, Costello T, Alt E, et al.: Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS 2002, 16:1700-1701.
27. National Institute of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. Hepatology 2002, 36(5):S3-S20.
28. Soriano V, Pouti M, Sulkowski M, et al.: Care of patients with hepatitis C and HIV coinfection. AIDS 2004, 18:1-12.
29. Thio C, Seaherg E, Skolasky K, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter AIDS Cohort Study (MACS), Lancet 2002, 360:1921-1926.
30. Kellerman S, Hanson D, McNaghten A, et al.: Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects, J Infect Dis 2003, 188:571-577.
31. Sheng WH, Chen MY, Hsieh SM, et al.: Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004, 38:1471-1477.
32. Rehermann B: Immune responses in hepatitis B virus infection. Semin Liver Dis 2003, 23:21-37.
33. Bodsworth NJ, Cooper DA, Donovan B: The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138-1140.
34. Rector W, Govindarajan S, Horsburgh C, et al.: Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to HIV. Am J Gastroenterol 1988, 83:262-266.
35. Hollinger FB: Hepatitis B virus. In Virology, edn 3. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia: Lippincott-Raven Publishers; 1997:2738-2808.
36. Soriano V, Puoti M, Bonacini M, et al.: Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an international HBV/HIV Panel, AIDS 2005, 19:221-240.
37. Allen ML, Deslauriers M, Andrews CW, et al.: Lamivudine Clinical Investigation Group. Identification and characterization of mutations in hepatitis b virus resistant to lamivudine. Hepatology 1998, 27:1670-1677.
38. Thibault V, Benhamou Y, Seguret C, et al.: Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999, 37:3013-3016.
39. Bessesen M, Ives D, Condreay L, et al.: Chronic active hepatitis B exacerbations in HIV-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 285:1032-1035.
40. Gish RG, Leung NW, Wright TL, et al.: Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002, 46:1734-1740.
41. Lau GK, Tsiang M, Hou J, et al.: Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000, 32:394-399.
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800-807.
43. Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-816.
44. Peters MG, Hann HW, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91-101.
45. Benhamou Y, Bochet M, Thibault V: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label study. Lancet 2001, 358:718-723.
46. Angus P, Vaughan R, Xiong S, et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV DNA polymerase. Gastroenterology 2003, 125:292-297.
47. Nunez M, Perez-Olmeda M, Diaz B, et al.: Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine. AIDS 2002, 16:2352-2354.
48. Peters M, Anderson J, Lynch P, et al.: Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are coinfected with HIV: results of ACTG A5127. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005..
49. Saumoy M, Vidal F, Peraire J, et al.: Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004, 18:1741-1742.
50. Van Bommel F, Wunsche T, Mauss S, et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40:1421-1425.
51. Callens S, De Roo A, Colebunders R: Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 2003, 47:262-263.
52. Ristig MB, Crippin J, Aberg JA, et al.: Tenofivir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/ hepatitis B virus-coinfected individuals for whom interferon-a and lamivudine therapy have failed. J Infect Dis 2002, 186:1844-1847.
53. Levine S, Hernandez D, Yamanaka G, et al.: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002, 46:2525-2532.
54. Tenney DJ, Levine SM, Rose RE, et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004, 48:3498-3507.
55. Soriano V, Puoti M, Bonacini M, et al.: Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an international HBV/HIV panel. AIDS 2005, 19:221-240.
56. Pessoa W, Gazzard B, Huang A, et al.: Entecavir in HIV/HBV-co-infected patients: safety and efficacy in a phase II study (ETV-038). Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22-25, 2005 (abstract 123).
57. Weltman MD, Brotodihardjo A, Crewe ER, et al.: Coinfection with hepatitis B and C or B, and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995, 2:39-45.
58. Sagnelli E, Pasquale N, Coppola N, et al.: Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2003, 32:144-148.
59. Kew MC, Yu MC, Kedda MA, et al.: The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997, 112:184-187.
60. Cacciola I, Pollicino T, Squadrito G, et al.: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999, 341:22-26.
61. Sagnelli E, Coppola N, Scolastico C, et al.: HCV genotype and silent HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol 2001, 64:350-355.
62. Villa E, Grottola A, Buttafoco P, et al.: High doses of α-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001, 96:2973-2977.
63. Zignego A, Fontana R, Puliti S, et al.: Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 1997, 142:535-544.
64. Fukuda K, Ishimura N, Hamamoto S, et al.: Coinfection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in liver. J Med Virol 2001, 63:220-227.
65. Tsai SL, Liaw YF, Yeh CT, et al.: Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus. Hepatology 1995, 21:908-912.
66. Wang YM, Ng WC, Lo SK: Suppression of hepatitis C virus by hepatitis B virus in coinfected patients at the national university hospital of Singapore. J Gastroenterology 1999:481-485.
67. Koike K, Yasuda K, Yotsuyanagi H, et al.: Dominant replication of either virus in dual infection with hepatic viruses B and C. J Med Virol 1995, 45:236-239.
68. Keeffe EB, Dieterich DY, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004, 2:87-106.